Journal of Cancer Therapy

Volume 6, Issue 12 (November 2015)

ISSN Print: 2151-1934   ISSN Online: 2151-1942

Google-based Impact Factor: 0.30  Citations  h5-index & Ranking

Three Protocols Designed to Individualize and Maximize Anti-Cancer Drug Therapy

HTML  XML Download Download as PDF (Size: 1361KB)  PP. 1103-1113  
DOI: 10.4236/jct.2015.612120    2,864 Downloads   3,619 Views  Citations

ABSTRACT

The role that attaining maximum drug dosage intensity plays in many anti-cancer protocols is a major one, particularly in those protocols that attempt to totally eradicate the neoplasm. A classic approach to facilitate this process utilizes stem cell transplants as well as the use of hematopoetic growth factors. However, problems arise with both allogenic and autologous transplants as well as from the significant variability in drug tolerance between individual patients. With average fixed dose protocols, these problems substantially limit the ability to optimize drug dosage. We attempted to circumvent this difficulty by using low dose continuous infusional therapy of variable duration depending upon the patient’s response, together with simultaneous hematopoietic growth factor support. This paper presents our results with three drugs, doxorubicin, ifosphamide, and vinorelbine. With these protocols, we were able to individualize and optimize the amount of drug delivered to each patient, as well as to substantially increase the drug dosage intensity of each of these agents.

Share and Cite:

Weiss, A. and Stoloff, I. (2015) Three Protocols Designed to Individualize and Maximize Anti-Cancer Drug Therapy. Journal of Cancer Therapy, 6, 1103-1113. doi: 10.4236/jct.2015.612120.

Copyright © 2024 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.